FUS — Fused in Sarcoma

Introduction

Fus — Fused In Sarcoma is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

FUS (Fused in Sarcoma) is a gene located on chromosome 16p11.2 that encodes an RNA-binding protein involved in multiple aspects of RNA metabolism, including transcription, splicing, transport, and translation. FUS is highly expressed in neuronal tissues and plays critical roles in neuronal development, function, and survival. Mutations in FUS are causally linked to amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), representing a key intersection between these two neurodegenerative disorders [1][2].

The FUS protein belongs to the FET (FUS, EWSR1, TAF15) family of RNA-binding proteins, which are characterized by their involvement in chromosomal translocations that generate oncogenic fusion proteins in various cancers. However, the focus of this page is on FUS’s normal physiological functions and its pathogenic role in neurodegeneration.

Protein Structure and Domains

The FUS protein (526 amino acids, ~59 kDa) contains several distinct structural domains that mediate its diverse functions:

1. N-terminal low-complexity (LC) domain: This glycine-rich region (amino acids 1-214) is enriched in tyrosine, glutamine, serine, and glycine residues. The LC domain is involved in protein-protein interactions and is critical for phase separation and liquid-liquid phase separation (LLPS) behavior [3][4].

2. RNA recognition motif (RRM): Located in the central region (amino acids 285-371), the RRM specifically binds RNA sequences and is essential for FUS’s function in RNA processing [5].

3. Zinc finger (ZnF) domain: This CCHC-type zinc finger (amino acids 422-453) contributes to RNA binding specificity and protein interactions [6].

4. C-terminal prion-like domain: Similar to the N-terminal LC domain, this region (amino acids 456-526) contains prion-like sequences that can undergo aggregation in disease states [7].

Biological Functions

RNA Processing

FUS is a multifunctional RNA-binding protein involved in:

• Transcription regulation: FUS interacts with RNA polymerase II and various transcription factors to regulate gene expression [8].

• Alternative splicing: FUS participates in the splicing machinery, influencing the inclusion or exclusion of specific exons in target mRNAs [9].

• RNA transport: In neurons, FUS localizes to dendritic and synaptic compartments, where it participates in RNA transport and local translation [10].

• mRNA stability: FUS helps stabilize certain mRNA transcripts and regulates their degradation [11].

DNA Damage Response

FUS plays a role in the cellular response to DNA damage:

• FUS is recruited to sites of DNA double-strand breaks

• It interacts with proteins involved in homologous recombination and non-homologous end joining

• Loss of FUS function may contribute to genomic instability in neurons [12]

Neuronal Development

During development, FUS is essential for:

• Neuronal differentiation and maturation

• Synapse formation and function

• Axonal growth and guidance

Role in Neurodegeneration

Amyotrophic Lateral Sclerosis (ALS)

Mutations in FUS account for approximately 5-10% of familial ALS cases and rare cases of sporadic ALS [13]. The majority of disease-causing mutations cluster in the C-terminal nuclear localization signal (NLS) region, which impairs FUS nuclear import. Pathological hallmarks include:

• Cytoplasmic FUS aggregates: ALS-associated mutations cause FUS to accumulate in the cytoplasm, where it forms insoluble aggregates [14].

• Nuclear depletion: Impaired nuclear import leads to loss of nuclear FUS function.

• RNA metabolism dysregulation: Altered splicing and transport of critical neuronal mRNAs.

• Stress granule formation: FUS is incorporated into stress granules under cellular stress conditions [15].

Frontotemporal Dementia (FTD)

FUS pathology is also observed in certain subtypes of FTD, particularly in cases with motor neuron disease-like features:

• FUS-positive inclusions are found in neurons and glia

• The distribution of FUS pathology correlates with clinical symptoms

• Some FTD cases show overlap with ALS pathology [16]

Mechanisms of Neurotoxicity

Several mechanisms have been proposed to explain how FUS mutations lead to neurodegeneration:

1. Loss of nuclear function: Reduced nuclear FUS impairs RNA processing and DNA repair.

2. Gain of toxic cytoplasmic function: Aggregated FUS may sequester other proteins and RNAs.

3. Axonal transport defects: FUS mutations disrupt mitochondrial dynamics and transport.

4. Excitotoxicity: Altered glutamate transporter expression may increase excitotoxic vulnerability.

5. Mitochondrial dysfunction: FUS mutations impair mitochondrial function and energy metabolism [17].

Therapeutic Approaches

Gene Therapy Strategies

• Antisense oligonucleotides (ASOs): ASOs targeting mutant FUS mRNA are in development to reduce toxic FUS protein levels [18].

• CRISPR-based approaches: Gene editing to correct disease-causing mutations is being explored.

• ** AAV delivery**: Viral vectors can deliver therapeutic genes or ASOs to the central nervous system.

Small Molecule Approaches

• Kinase inhibitors: Compounds targeting kinases involved in FUS phosphorylation may reduce aggregation.

• Aggregation inhibitors: Small molecules that prevent FUS aggregation are under investigation.

• RNA stabilizers: Compounds that restore normal RNA processing are being developed.

Symptomatic Treatments

• Riluzole and edaravone provide modest benefits in ALS

• Multidisciplinary care including ventilatory support, physical therapy, and nutritional support

• Management of FTD symptoms with behavioral and pharmacological interventions

Animal Models

Multiple animal models have been developed to study FUS-related neurodegeneration:

• Transgenic mice: Expressing human FUS mutations recapitulate key aspects of ALS/FTD

• Zebrafish models: Allow rapid screening of FUS mutations and therapeutic compounds

• Induced pluripotent stem cells (iPSCs): Patient-derived neurons provide human disease models [19]

See Also

• ALS — Amyotrophic Lateral Sclerosis

• TDP-43 Protein — Related RNA-binding protein in ALS/FTD

• RNA Binding Proteins in Neurodegeneration — FUS in the context of RNA metabolism dysregulation

• Stress Granule Homeostasis — FUS incorporation into stress granules

• Spliceosome Dysfunction — FUS role in alternative splicing

Relationship to Alzheimer’s and Parkinson’s Disease

While FUS is primarily associated with ALS and FTD, emerging research suggests potential indirect connections to Alzheimer’s disease (AD) and Parkinson’s disease (PD) through shared pathological mechanisms:

Alzheimer’s Disease Connection

• RNA metabolism dysfunction: Both AD and FUS-related disorders involve dysregulated RNA processing. Proteins like TDP-43 show involvement in AD brain tissue, similar to FUS pathology.

• Stress granule formation: FUS incorporation into stress granules is a feature shared with other neurodegenerative diseases, including AD. Persistent stress granules may contribute to proteostasis failure in AD.

• DNA damage response: FUS plays a role in DNA repair, and impaired DNA damage response is a feature of both FUS-ALS and AD neurons.

• Tau protein interaction: Studies suggest FUS may interact with tau protein pathology, potentially influencing neurofibrillary tangle formation in AD.

Parkinson’s Disease Connection

• Alpha-synuclein pathology: While FUS does not directly aggregate in typical PD, both FUS mutations and alpha-synucleinopathies involve stress granule dynamics and RNA dysregulation.

• Mitochondrial dysfunction: FUS mutations impair mitochondrial function, a core pathological feature in PD.

• Excitotoxicity mechanisms: Shared mechanisms of excitotoxic vulnerability may link FUS-related neurodegeneration with PD.

• Dopaminergic neuron vulnerability: Research on FUS in motor neurons may inform understanding of selective vulnerability in PD.

Therapeutic Implications

Understanding these connections may lead to shared therapeutic strategies:

• RNA-targeted therapies: ASOs and RNA modulators developed for FUS-ALS may benefit AD/PD

• Stress granule modulators: Compounds targeting stress granule dynamics could have broad applicability

• Mitochondrial protectors: Shared mitochondrial protective strategies may benefit multiple neurodegenerative conditions

See also: Stress Granule Homeostasis, Mitochondrial Dysfunction in Neurodegeneration, RNA Metabolism in Neurodegeneration

The study of Fus — Fused In Sarcoma has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Brain Atlas Resources

• Allen Human Brain Atlas: Expression data for FUS

• Allen Cell Type Atlas: Cell type expression data

• BrainSpan Atlas: Developmental transcriptome data

Pathway Diagram

flowchart TD
    A["FUS Gene<br/>16p11.2 -> BFUS Protein<br/>RNA-binding protein"]
    B  -->  C["Normal Function<br/>RNA Processing"]
    C  -->  D["Transcription Regulation"]
    D  -->  E["RNA Splicing"]
    E  -->  F["mRNA Transport"]
    F  -->  G["Local Translation"]
    G  -->  H["Synaptic Function"]
    
    I["FUS Mutations<br/>R521 C, R522G, P525L"] --> J["Misfolding"]
    J  -->  K["Aggregation"]
    K  -->  L["Cytoplasmic Inclusions"]
    L  -->  M["RNA Dysregulation"]
    
    J  -->  N["Nuclear Import Defect"]
    N  -->  O["Nuclear Pore Stress"]
    O  -->  P["Transcriptional Dysregulation"]
    
    M  -->  Q["Proteostasis Disruption"]
    Q  -->  R["Motor Neuron Degeneration<br/>ALS/FTD"]
    
    S["Stress Granules<br/>Pathological -> K"]
    
    style A fill:#1a0a1f,stroke:#333
    style R fill:#3b1114,stroke:#333

Disease Mechanism Summary

Recent Research (2024-2025)

Recent advances in FUS-linked ALS research have revealed new mechanisms and therapeutic approaches:

• FUS Mutations in ALS: Comprehensive review of ALS caused by FUS mutations with broad clinical implications^{1Amyotrophic lateral sclerosis caused by FUS mutations: advances with broad implications (2025)2025 · PMID 39862884Open reference}.

• Neuromuscular Denervation: The CCL2-CCR2 axis drives neuromuscular denervation in ALS^{2The CCL2-CCR2 axis drives neuromuscular denervation in amyotrophic lateral sclerosis (2025)2025 · PMID 40750607Open reference}.

• Therapeutic Approaches: Carboplatin restores neuronal toxicity in FUS-linked ALS^{3Carboplatin restores neuronal toxicity in FUS-linked amyotrophic lateral sclerosis (2025)2025 · PMID 39359088Open reference}.

• Drug Delivery: Lipid nanoparticles and transcranial focused ultrasound enhance ASO delivery for ALS therapy^{4Lipid nanoparticles and transcranial focused ultrasound enhance ASO delivery to the murine brain for ALS therapy (2025)2025 · PMID 39645085Open reference}.

• DNA Damage Response: DNA damage response defects induced by TDP-43 and mutant FUS inclusions^{5DNA damage response defects induced by TDP-43 and mutant FUS cytoplasmic inclusions (2025)2025 · PMID 40437235Open reference}.

• Extracellular FUS: Release of FUS into extracellular space regulated by its prion-like domain^{6Release of FUS into the extracellular space is regulated by its amino-terminal prion-like domain (2025)2025 · PMID 39737526Open reference}.

External Links

• NCBI Gene: FUS

• UniProt: P35637

• OMIM: 137070

• Ensembl: ENSG00000089280

• ALS Association

• ALS Therapy Development Institute

Pathogenic Mutations Comparison

FUS Protein Domains and Functions